IDH1 and neoplasm: An Open-label, Non-randomized, Multicenter phase I study to determine the maximum tolerated or recommended phase II dose of oral mutant IDH1 inhibitor BAY1436032 and to characterize its safety, Tolerability, Pharmacokinetics and preliminary pharmacodynamic and anti-tumor activity in patients with IDH1-R132X-mutant advanced solid tumors